Track CRNX's AI-powered predictions, market trends, and investment insights.
StockTwits Mentions
0
CRNX has been mentioned an estimated 0 times on StockTwits over the last 24 hours.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedCrinetics Pharmaceuticals is currently unprofitable, as reflected in its negative EPS and PE ratio. The lack of positive earnings suggests the company is still in an investment and development phase rather than a cash-generating phase. From a pure financial-performance standpoint, this positions the stock as higher risk and dependent on future execution and clinical or commercial milestones.
The stock trades at $34.47, below its 200-day moving average of $41.65, and has declined 6.3% over the last month, indicating recent weakness and a bearish intermediate trend. Trading below the 200-day moving average generally signals that the market is cautious or reassessing the company’s outlook. Without evidence of oversold conditions (e.g., RSI not provided), the technical picture leans negative in the near term.
Alternative data for Crinetics Pharmaceuticals show modest but steady engagement and hiring, with no signs of sharp deterioration or aggressive expansion. Web traffic is moderate and job openings are stable, suggesting a steady-state operating posture rather than a major ramp-up or contraction. LinkedIn follower growth stands out as relatively stronger than other social channels, hinting at growing professional and industry interest.
Overall, the picture for Crinetics Pharmaceuticals is neutral: financials and technicals are currently bearish, but alternative data suggest a stable underlying business with gradually rising professional interest. The stock appears to be in a consolidation or reassessment phase where future clinical, regulatory, or partnership milestones will likely drive the next major move. Investors are effectively betting on long-term pipeline success rather than near-term earnings strength.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
You don't hold CRNX in your mock portfolio yet.
CRNX StockTwits activity shows 21 mentions over the past seven days, a modest but measurable level of retail trader engagement for a mid-cap biotech with a $3.7 billion market cap. The conversation is relatively contained compared to high-momentum names, but the timing is notable — chatter is coinciding with a sharp single-session gain of 4.7%, pushing the stock to $34.63. Traders on StockTwits appear to be reacting to near-term price movement rather than driving it, with discussion largely centered on the day's surge and what it signals for short-term direction.
Context matters when reading StockTwits data. CRNX's 21 mentions arrive alongside elevated volume of over 1 million shares traded — well above typical sessions — suggesting the price move has genuine market participation behind it, not just social noise. However, TrendEdge's AI Score of 5 out of 10 signals a neutral overall outlook, meaning the StockTwits buzz has not yet translated into a broadly bullish technical or fundamental setup. Traders monitoring CRNX should treat the social uptick as a prompt to investigate further rather than a standalone buy signal.
TrendEdge aggregates CRNX StockTwits mentions alongside Reddit thread activity, options flow, and proprietary AI scoring to give traders a multi-signal view of market sentiment. A single data point — like mention count — rarely tells the full story. By combining social volume trends with price action, institutional indicators, and a composite AI score, TrendEdge helps users distinguish between genuine momentum shifts and short-lived retail reactions. This layered approach is especially critical for biotech names like CRNX, where sentiment can swing sharply on clinical or regulatory news.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
19,607
Twitter Followers
1,074
Instagram Followers
179
LinkedIn Followers
52,227
Job Postings
40
LinkedIn Employees
613
News Mentions
0
Key Metrics
